2022, Number 4
Cardiovasc Metab Sci 2022; 33 (4)
Consensus Statement of the Mexican College of Interventional Cardiology and Endovascular Therapy on percutaneous coronary treatment with drug-coated balloon. The COMECITE DCB consensus statement+
Moguel-Ancheita, Rafael; Olvera-Ruiz, Rafael; Moreno-Buenrostro, Javier; Ramos-Cházaro, Enrique; Lozoya-Morales, José Juan; Bautista-López, Germán Ramón; Bayardo-Solórzano, Héctor Vicente; Castillo-Gutiérrez, Mauricio Adolfo; Picos-Bovio, Eva María; Beltrán-Nevárez, Octavio; Muñoz-Beltrán, Leocadio Gerardo; Cabrera-Arroyo, Carlos Gustavo
ABSTRACT
Percutaneous coronary intervention (PCI) is currently the prevalent revascularization method for the last forty years due to its efficacy, low complication rate, and minimal invasion with still pending restenosis solution. The dominant strategy to improve PCI for long-lasting benefits is the utilization of drug-eluting stents (DES), even though the current in-stent restenosis (ISR) rate is ≈10%, plus the inconvenience of foreing body insertion, thrombosis risk, bleeding in high-risk patients, jailing branches potential and possible multiple metal layers after ISR treatment. Drug coated-balloon (DCB) may reduce restenosis without leaving a foreign body and adding metal layers. Several expert group consensus statements and updating report publications, support their utilization for almost a decade. The present paper is from the Mexican College of Interventional Cardiology and Endovascular Therapy (COMECITE) statement regarding current DCB utilization and recommendations in ISR, small vessels, bifurcations, left anterior descendent/left main coronary and acute myocardial infarction.